1286748-19-3Relevant academic research and scientific papers
Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer
Dong, Qing,Dougan, Douglas R.,Gong, Xianchang,Halkowycz, Petro,Jin, Bohan,Kanouni, Toufike,O'Connell, Shawn M.,Scorah, Nicholas,Shi, Lihong,Wallace, Michael B.,Zhou, Feng
scheme or table, p. 1315 - 1319 (2011/04/16)
A novel 5-phenylamino-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione series of MEK inhibitors has been developed using structure-based drug design. Lead optimization of this series led to the discovery of TAK-733. This was advanced to Phase I clinical studies for cancer treatment.
